TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
Commentary|Videos|January 5, 2024
Advancements in Obesity Medicine in 2023: Breakthroughs and Shifting Perspectives on Treatment
Author(s)Sydney Jennings
Advertisement
"How does 2023 compare to previous years in terms of advancements in obesity medicine?
Patient Care Online asked this question in a recent interview with Angela Fitch, MD, president of the Obesity Medicine Association, in a recent interview. In the video below, Dr Fitch discusses the approval of
Dr Fitch is also the founder and chief medical officer at knownwell and the former co-director of the Massachusetts General Hospital Weight Center and faculty at Harvard Medical School.
Advertisement
Related to this article
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
2
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
3
Menopause Diagnoses Documented in Just 7.8% of Midlife Women's Outpatient Visits, Study Finds
4
More Frequent Physical Activity Linked to Fewer Perimenopause Symptoms in Global Study
5